Performance guarenteed

### CD51 (Integrin alpha V) Monoclonal Antibody (RMV-7), eBioscience™

#### **Product Details**

Size	100 µg
Species Reactivity	Mouse
Published Species	Mouse, Human
Host/Isotype	Rat / IgG1, kappa
Class	Monoclonal
Туре	Antibody
Clone	RMV-7
Conjugate	Unconjugated
Form	Liquid
Concentration	0.5 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2
Contains	0.09% sodium azide
Storage conditions	4° C
RRID	AB_467296

Applications	Tested Dilution	Publications
Immunohistochemistry (IHC)	-	1 Publication
Flow Cytometry (Flow)	1 µg/test	9 Publications
Immunoprecipitation (IP)	Assay-Dependent	-
Neutralization (Neu)	Assay-Dependent	1 Publication
Functional Assay (FN)	Assay-Dependent	-

#### **Product Specific Information**

Description: The RMV-7 monoclonal antibody reacts with the mouse CD51 molecule, the integrin alpha v chain. This approximately 120 kDa surface molecule non-covalently associates with the beta subunits of the integrin family including beta3 (CD61), beta1 (CD29), beta5 and beta6 to form receptors for extracellular matrix components. Heterodimers of CD51/CD61 are expressed by platelets, T cells and granulocytes and mediate adhesion to fibrinogen, fibronectin, vitronectin and thrombospondin.


Applications Reported: The RMV-7 antibody has been reported for use in flow cytometric analysis, immunoprecipitation, and functional assays. Soluble RMV-7 blocks adhesion to fibronectin and vitronectin and immobilized RMV-7 induces activation. (Please use Functional Grade purified RMV-7, cat. 16-0512, in functional assays.).

Applications Tested: The RMV-7 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 1  $\mu$ g per test. A test is defined as the amount ( $\mu$ g) of antibody that will stain a cell sample in a final volume of 100  $\mu$ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

#### Product Images For CD51 (Integrin alpha V) Monoclonal Antibody (RMV-7), eBioscience™



#### CD51 (Integrin alpha V) Antibody (14-0512-82) in Flow

Staining of C57BI/6 bone marrow cells with 1 µg of Rat IgG1 Isotype Control Purified (Product # 14-4301) (open histogram) or 1 µg of Anti-Mouse CD51 (Integrin alpha V) Purified (filled histogram) followed by Anti-Rat IgG PE (Product # 12-4822). Cells in the large scatter population were used for analysis.

View more figures on thermofisher.com

#### **□** 11 References

#### Immunohistochemistry (1)

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine

## A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.

"Published figure using CD51 (Integrin alpha V) monoclonal antibody (Product # 14-0512-82) in Immunohistochemistry" Authors: Warram JM,Sorace AG,Saini R,Umphrey HR,Zinn KR,Hoyt K

#### Flow Cytometry (9)

Neutralization (1)

Nature communications A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation.	<b>Year</b> 2020
"Published figure using CD51 (Integrin alpha V) monoclonal antibody (Product # 14-0512-82) in Flow Cytometry"	
Authors: Kim JM,Yang YS,Park KH,Ge X,Xu R,Li N,Song M,Chun H,Bok S,Charles JF,Filhol-Cochet O,Boldyreff B, Dinter T,Yu PB,Kon N,Gu W,Takarada T,Greenblatt MB,Shim JH	
Nature communications	Year

## Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias.

"Published figure using CD51 (Integrin alpha V) monoclonal antibody (Product # 14-0512-82) in Flow Cytometry" Authors: Chaudhury S,O'Connor C,Cañete A,Bittencourt-Silvestre J,Sarrou E,Prendergast Á,Choi J,Johnston P,Wells CA,Gibson B,Keeshan K

View more Flow references on thermofisher.com

2018

# Nature communications Year The matricellular protein CCN1 mediates neutrophil efferocytosis in 2015 cutaneous wound healing. Species "14-0512 was used in Blocking experiments to establish the matricellular protein, CCN1, as a critical opsonin in skin Mouse "14-0512 was used in Blocking experiments to establish the matricellular protein, CCN1, as a critical opsonin in skin Mouse

#### More applications with references on thermofisher.com

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty growide herein is valid only when used by property trained individuals. Unless otherwise stated in the Documentation, this warranty is morely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample furnication to such model or sample furnication. The WarRANTIES CEPRESS OR INPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S SCLILUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANT PERFIDIO IS LIMITED TO REPAR, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS DURING THE WARRANT PROTOCID DURING THE RUND CONF THE NON-CONFORMING PRODUCTS SOLE OPTION. THERE IS NO BUILGATION TO REFAR, REPLACE OR REFUND FOR THE RONDUCTS MAIN PROTOCID DURING THE WARRANT PROTOCID DURING THE RUND CONF THE NON-CONFORMING PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. UN AMANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. IN A MANNER FOR WHICH

**Year** 2011